PBL given go ahead to advance anthrax vaccine to first phase
The phase I study combines Blue Willow’s novel intra-nasal NanoVax system with PBL’s recombinant protective antigen for anthrax.
Read More
Tag: Blue Willow
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
